Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.53 |
| ▸ | USP2 | O75604 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | CASP1 | P29466 | 6/20 | 0.45 |
| ▸ | CASP7 | P55210 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | GLA | P06280 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19287945 | 0.87 | ALDH1A1 (0.59) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL19570833 | 0.84 | ALDH1A1 (0.45) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL24758820 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL18735005 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL19574739 | 0.83 | ALDH1A1 (0.67) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL29787036 | 0.81 | KMT2A (0.78) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL28564674 | 0.76 | ALDH1A1 (0.63) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL31267435 | 0.69 | MEN1 (1.00) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL194764 | 0.69 | MEN1 (1.00) | MEN1KMT2AUSP2TDP1HTT | |
| SCHEMBL29440640 | 0.65 | MEN1 (0.73) | MEN1KMT2AUSP2TDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-23 | — | — | US | disclosed |
| US-20220162598-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-26 | — | — | US | disclosed |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-25 | — | — | US | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-10724035-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-28 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-19 | — | — | US | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | MEN1 1483/4885KMT2A 1427/4885USP2 4071/4885 |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | MEN1 3713/4885KMT2A 1986/4885USP2 3575/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | MEN1 4562/4885KMT2A 1618/4885USP2 3779/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | MEN1 4700/4885KMT2A 4217/4885USP2 3704/4885 |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | RNGTT, NSUN2, POLRMT | MEN1 1927/4885KMT2A 918/4885USP2 4414/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | MEN1 2775/4885KMT2A 698/4885USP2 3439/4885 |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | MEN1 4562/4885KMT2A 1618/4885USP2 3779/4885 |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | MEN1 1927/4885KMT2A 918/4885USP2 4414/4885 |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | MEN1 3713/4885KMT2A 1986/4885USP2 3575/4885 |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | MEN1 1927/4885KMT2A 918/4885USP2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.